Medline Inc. (MDLN) SEC Filings & Earnings Calls
EquiReason read 12 Medline Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-21 — Medline initiated voluntary field action removing all Medline Brand beds from market; net sales of affected products ~$60M; estimated costs up to $220M; expects no material impact .
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 44.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
21 Oct 20268-K · 7.01Medline initiated voluntary field action removing all Medline Brand beds from market; net sales of affected products ~$60M; estimated costs up to $220M; expects no material impact on FY2026 guidance.open
Figures in the filing · each found in the filing text
| Net sales of affected products · Medline Brand · FY2026 | $60M | |
| Estimated costs associated with field action · 2026-2027 | $220M |
Guidance
Company currently does not expect this action to have a material impact on its financial results for fiscal year 2026, including its full year 2026 guidance provided on August 5, 2026.
Risks flagged
Product recall and market exit of Medline Brand beds could lead to significant costs up to $220M, inventory impairment, and customer credits, though management expects no material impact on FY2026 guidance.
“voluntary field action involving the removal, discontinuation, and market exit of all Medline Brand beds ... estimated costs of up to $220 million”
15 Oct 20268-K · 5.02Director Joseph P. Baratta resigns from Medline board effective Dec 31, 2026, coinciding with departure from Blackstone; no disagreement with company.open
Risks flagged
Loss of board member with private equity perspective, but no disagreement or operational impact cited
“Mr. Baratta's decision coincides with his previously announced departure from Blackstone Inc. and is not the result of any disagreement with the Company related to the Company's operations, policies, or practices.” · word for word
5 Aug 20268-K · 2.02Net sales $7.70B (+12% y/y); net income $139M (-58% y/y); organic sales growth 11.5; Guidance: Organic sales guidance raised to 9-10% (from 8.5-9.5%); Adj EBITDA guidance cut to $3.3-3.4B (from $3.5-3.6B)earningsopen
Figures in the filing · each found in the filing text
| net_sales · Q2-2026 | $7.70B | +12% y/y |
| net_income · Q2-2026 | $139M | -58% y/y |
| organic_sales_growth · Q2-2026 | 11.5% | |
| free_cash_flow · H1-2026 | $920M | |
| capital_expenditures · H1-2026 | $207M |
Guidance
Organic sales guidance raised to 9-10% (from 8.5-9.5%); Adj EBITDA guidance cut to $3.3-3.4B (from $3.5-3.6B)
Raised organic sales guidance due to strong demand; cut EBITDA guidance due to inflation, investments, and retail softness.
Risks flagged
Fire at Tracy distribution center caused $336M loss before insurance; quality remediation costs; retail channel softness; Middle East conflict inflationary pressure.
“Losses of $336 million related to the fire; quality remediation efforts; retail channel softness; higher than expected inflationary pressure from the Middle East conflict.” · word for word
5 Aug 202610-QMedline reported Q2 2026 results with 11.6% revenue growth but a $336M fire loss at Tracy distribution center, partially offset by strong cash flow and debt refinancingopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $7.68B | +12% y/y |
| Net sales · H1-2026 | $15.04B | +11% y/y |
| Gross profit · Q2-2026 | $2.21B | +16% y/y |
| Operating income · Q2-2026 | $395M | -39% y/y |
| Net income attributable to Medline Inc. · Q2-2026 | $60M | -82% y/y |
| Net cash provided by operating activities · H1-2026 | $1.13B | +28% y/y |
| Cash and cash equivalents · 2026-06-27 | $2.33B |
Risks flagged
Distribution center fire disruption
“On June 11, 2026, a fire destroyed the Company's distribution center in Tracy, California. ... The Company has estimated incurred losses of $336 million” · word for word
Insurance recovery uncertainty
“As of June 27, 2026, discussions with the Company’s insurers are ongoing, and, as such, no insurance recoveries have been recorded.” · word for word
9 Jul 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Key executive departure may cause operational disruption.
“COO retirement for health reasons; search for successor launched.”
2 Jun 20268-K · 1.01, 2.03, 8.01Selling stockholders completed underwritten public offering of 72,554,594 shares at $37.00 per share; also issued senior secured notes due 2031/2033 and amended credit agreement.open
Risks flagged
Increased leverage from new debt issuance, though proceeds used to repay existing obligations.
“New debt of $4.75B issued, but net leverage impact unclear as proceeds repay existing debt.”
6 May 202610-QNet sales $7.35B (+11% y/y); Gross profit $1.84B (+1% y/y); Operating income $422M (-26% y/y)open
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $7.35B | +11% y/y |
| Gross profit · Q1-2026 | $1.84B | +1% y/y |
| Operating income · Q1-2026 | $422M | -26% y/y |
| Net income · Q1-2026 | $239M | -26% y/y |
| Cash and cash equivalents · 2026-03-28 | $2.24B | |
| Inventories, net · 2026-03-28 | $4.81B |
Risks flagged
Margin compression risk
“Operating income $422 (2026) vs $571 (2025), decrease of 26%.”
Leverage risk
“Long-term borrowings $12,495M as of March 28, 2026.”
6 May 20268-K · 2.02Net sales $7.40B (+11% y/y); Organic Sales growth 10.1; Net income $239M (-26% y/y); Guidance: Organic Sales guidance raised to 8.5%-9.5% from 8%-9%earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $7.40B | +11% y/y |
| Organic Sales growth · Q1-2026 | 10.1% | |
| Net income · Q1-2026 | $239M | -26% y/y |
| Adjusted EBITDA · Q1-2026 | $776M | -11% y/y |
| Diluted earnings per share · Q1-2026 | $0.16 | |
| Adjusted Diluted EPS · Q1-2026 | $0.33 | |
| Net cash provided by operating activities · Q1-2026 | $412M | |
| Free Cash Flow · Q1-2026 | $316M |
Guidance
Organic Sales guidance raised to 8.5%-9.5% from 8%-9%
Raising Organic Sales guidance reflects strong demand; margin pressure from tariffs and costs; maintaining Adjusted EBITDA outlook.
Risks flagged
Tariff impact on cost of goods sold pressuring margins; net income and Adjusted EBITDA declined despite revenue growth.
“higher costs of goods sold including the impact of tariffs” · word for word
Higher operating expenses to support new customer growth and IPO bonus may persist.
“higher operating expenses to support new customer growth and an employee bonus related to the Company’s IPO” · word for word
23 Apr 2026DEF 14AMedline Inc. filed its 2026 proxy statement (DEF 14A) detailing executive compensation, IPO and secondary offering details, and governance matters.open
Figures in the filing · each found in the filing text
| Net Sales · FY2025 | $28.43B | +12% y/y |
| Net Income · FY2025 | $1.16B | -4% y/y |
| Adjusted EBITDA · FY2025 | $3.47B | +3% y/y |
| Free Cash Flow · FY2025 | $1.30B | -8% y/y |
| Organic Sales Growth · FY2025 | 10.5% | |
| Net Capital Expenditures · FY2025 | $447M | +26% y/y |
| Adjusted EBITDA Margin · FY2025 | 12.2% | |
| Plan Adjusted EBITDA · FY2025 | $3.60B | |
| Net Sales (Plan) · FY2025 | $28.43B | |
| IPO Proceeds · 2025-12-18 | $5.08B |
Risks flagged
Tax Receivable Agreement Liquidity Risk
“Our obligations under the Tax Receivable Agreement could have a substantial negative impact on our liquidity.” · word for word
Concentrated Ownership and Control
“Mozart HoldCo, Inc. beneficially owns 50.0% of Class B common stock, giving the Mills family significant voting power.”
Related Party Transactions
“Andrew J. Mills, a member of our board of directors, received an allocation of term loans under our Senior Secured Credit Facilities, of which $17.8 million and $17.6 million principal remained outstanding as of December 31, 2024 and 2025, respectively.” · word for word
25 Feb 20268-K · 2.02Net sales $7.80B (+15% y/y); Net income $180M (-38% y/y); Adjusted EBITDA $805M (-1% y/y); Guidance: FY2026 organic sales growth 8-9%, adjusted EBITDA $3.5-$3.6Bearningsopen
Figures in the filing · each found in the filing text
| Net sales · Q4-2025 | $7.80B | +15% y/y |
| Net income · Q4-2025 | $180M | -38% y/y |
| Adjusted EBITDA · Q4-2025 | $805M | -1% y/y |
| Full year net sales · FY2025 | $28.40B | +12% y/y |
| Full year net income · FY2025 | $1.20B | -4% y/y |
| Full year Adjusted EBITDA · FY2025 | $3.50B | +3% y/y |
| Net cash provided by operating activities · FY2025 | $1.70B | |
| Free cash flow · FY2025 | $1.30B | |
| New customer signings · FY2025 | $2.40B |
Guidance
FY2026 organic sales growth 8-9%, adjusted EBITDA $3.5-$3.6B
Strong revenue growth with margin pressure from tariffs; guidance implies continued momentum.
Risks flagged
Tariff impact on cost of goods sold and margins.
“Higher costs of goods sold due to tariffs.” · word for word
IPO-related expenses and higher operating costs pressure profitability.
“Higher operating costs, including investments in headcount and IPO-related expenses.” · word for word
22 Dec 20258-K · 1.01, 3.03, 5.02, 5.03, 8.01IPO shares issued 248,439,654; IPO price per share $29.00; Debt repayment - Euro Term Loan $731Mopen
Figures in the filing · each found in the filing text
| IPO shares issued · Q4-2025 | 248,439,654 | |
| IPO price per share · Q4-2025 | $29.00 | |
| Debt repayment - Euro Term Loan · Q4-2025 | $731M | |
| Debt repayment - 2028 Term Loan · Q4-2025 | $3.29B |
Risks flagged
Post-IPO governance complexity with multiple director nomination agreements
“Director Nomination Agreements with Blackstone, Carlyle, Hellman & Friedman, Mills Family”
Government contract awards
federal awards · contract value, often multi-year| Date | Agency | Value | What for |
|---|---|---|---|
| 2026-09-22 | Department of Veterans Affairs | $82M | EXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF AUG 2026 |
| 2026-09-08 | Office of Assistant Secretary for Prepar | $7M | BPA CALL ORDER FOR RESP IV ADULT |
| 2026-08-20 | Department of Veterans Affairs | $87M | EXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF JULY 2026 |
| 2026-08-05 | Indian Health Service | $9M | MEDLINE FEDERAL BLUE. FUNDING FOR PURCHASE MEDICAL AND SURGICAL SUPPLIES FOR FEDERAL CUSTOMERS |
| 2026-07-20 | Department of Veterans Affairs | $81M | EXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF JUNE 2026 |
| 2026-06-26 | Department of Veterans Affairs | $84M | EXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF MAY 2026 |
| 2026-05-26 | Department of Veterans Affairs | $82M | EXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF APRIL 2026 |
| 2026-04-21 | Department of Veterans Affairs | $78M | EXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF MARCH 2026 |
| 2026-03-13 | Department of Veterans Affairs | $71M | EXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF JANUARY 2026 |
| 2026-03-13 | Department of Veterans Affairs | $68M | EXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF FEBRUARY 2026 |
Medline Inc. — questions
- What did Medline Inc. file recently?
- 12 SEC filings in the last 12 months. Latest: 8-K on 2026-10-21 — Medline initiated voluntary field action removing all Medline Brand beds from market; net sales of affected products ~$60M; estimated costs up to $220M; expects no material impact on FY2026 guidance.
Every figure on this page comes from Medline Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.